Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Enanta Pharmaceuticals, Inc. ENTA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
44/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$48.20
+229.5%

Enanta Pharmaceuticals, Inc. (ENTA) is a Biotechnology company in the Healthcare sector, currently trading at $14.63. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ENTA = $48 (+229.5% upside).

Valuation: ENTA trades at a trailing Price-to-Earnings (P/E) of -4.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.21.

Financials: revenue is $65M, -8.7%/yr average growth. Net income is $82M (loss), growing at +10.9%/yr. Net profit margin is -125.4% (negative). Gross margin is 93% (-7 pp trend).

Balance sheet: total debt is $201M against $65M equity (Debt-to-Equity (D/E) ratio 3.11, leveraged). Current ratio is 4.21 (strong liquidity). Debt-to-assets is 71.6%. Total assets: $281M.

Analyst outlook: 14 / 19 analysts rate ENTA as buy (74%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 35/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).

$48.20
▲ 229.46% Upside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Enanta Pharmaceuticals, Inc., the average price target is $48.20, with a high forecast of $87.00, and a low forecast of $20.00.
Highest Price Target
$87.00
Average Price Target
$48.20
Lowest Price Target
$20.00

ENTA SharesGrow Score Overview

52/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ENTA

✓
VALUE Pass
100/100
ENTA trades at a trailing Price-to-Earnings (P/E) of -4.1 (S&P 500 average ~25). Forward PEG 0.21 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $48, implying +228.1% from the current price $15. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
ENTA: -8.7%/yr revenue is, +10.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet ENTA: Debt-to-Equity (D/E) ratio 3.11 (leveraged), Current ratio is 4.21 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
ENTA: Gross margin is 93% (-7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 14 / 19 analysts rate ENTA as buy (74%). Analyst consensus target is $48 (+228.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ENTA: Net profit margin is -125.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.09-17.15
Volume91.36K
Avg Volume (30D)182.77K
Market Cap$339.66M
Beta (1Y)1.00
Share Statistics
EPS (TTM)-3.84
Shares Outstanding$21.34M
IPO Date2013-03-21
Employees131
CEOJay R. Luly
Financial Highlights & Ratios
Revenue (TTM)$65.32M
Gross Profit$60.74M
EBITDA$-70.78M
Net Income$-81.89M
Operating Income$-85.35M
Total Cash$188.86M
Total Debt$201.06M
Net Debt$168.76M
Total Assets$280.73M
Price / Earnings (P/E)-3.8
Price / Sales (P/S)5.2
Analyst Forecast
1Y Price Target$54.00
Target High$87.00
Target Low$20.00
Upside+269.1%
Rating ConsensusBuy
Analysts Covering19
Buy 74% Hold 16% Sell 11%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS29251M1062

Price Chart

Track all markets on TradingView
ENTA
Enanta Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
4.09 52WK RANGE 17.15

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 MRUS
MRUS
Merus N.V.
$90.00
+0.00%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message